Arcellx, Inc.

Arcellx, Inc. Stock Forecast & Price Prediction

Live Arcellx, Inc. Stock (ACLX) Price
$62.56

10

Ratings

  • Buy 10
  • Hold 0
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$62.56

P/E Ratio

P/E Ratio not available for ACLX

Volume Traded Today

$286,311

Dividend

Dividends not available for ACLX

52 Week High/low

75.10/30.88

Arcellx, Inc. Market Cap

$3.05B

🛑 Alert: These ten stocks could have higher potential than $ACLX 🛑

Before you buy ACLX you’ll want to see this list of ten stocks that have huge potential. Want to see if ACLX made the cut? Enter your email below

ACLX Summary

The Arcellx, Inc. (ACLX) share price is expected to increase by 27.88% over the next year. This is based on calculating the average 12-month share price estimate provided by 10 stock analysts who have covered ACLX. Price targets range from $70.00 at the low end to $85.00 at the high end. The current analyst consensus for ACLX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

ACLX Analyst Ratings

About 10 Wall Street analysts have assignedACLX 10 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Arcellx, Inc. to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ACLX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

ACLX stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

benjamin burnett
Stifel Nicolaus

Buy

$83.0

maintained

Jul 1, 2024
jason gerberry
Bank of America Securities

Buy

$84.0

rated

Jun 24, 2024
asthika goonewardene
Truist Financial

Buy

None

maintained

Jun 18, 2024
john newman
Canaccord Genuity

Buy

$85.0

maintained

Jun 4, 2024
biren amin
Piper Sandler

Buy

$70.0

initiatedcoverage

May 31, 2024
tyler van buren
TD Cowen

Buy

None

rated

May 13, 2024
cory kasimov
Evercore ISI

Buy

$85.0

initiatedcoverage

May 13, 2024
carter gould
Barclays

Buy

$73.0

maintained

May 10, 2024
gil blum
Needham

Buy

$81.0

reiterated

May 10, 2024
emily bodnar
H.C. Wainwright

Buy

$80.0

maintained

May 10, 2024
jack allen
Robert W. Baird

Buy

$77.0

maintained

May 10, 2024
sami corwin
William Blair

Buy

None

maintained

May 10, 2024
george farmer
Scotiabank

Buy

$82.0

reiterated

May 10, 2024
judah frommer
Credit Suisse

Buy

$81.0

initiatedcoverage

Mar 7, 2024
daina graybosch
Leerink Partners

Buy

$70.0

maintained

Feb 28, 2024
ashwani verma
UBS

Buy

$52.0

initiatedcoverage

Oct 17, 2023
kelsey goodwin
Guggenheim

Buy

None

maintained

Jun 20, 2023
raju prasad
William Blair

Buy

None

maintained

Dec 12, 2022

ACLX Company Information

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

ACLX
Arcellx, Inc. (ACLX)

When did it IPO

2022

Staff Count

130

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. Rami Elghandour

Market Cap

$3.05B

Arcellx, Inc. (ACLX) Financial Data

In 2023, ACLX generated $110.3M in revenue, which was a increase of inf% from the previous year. This can be seen as a signal that ACLX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$0

Revenue From 2021

$0

nan %
From Previous Year

Revenue From 2022

$0

nan %
From Previous Year

Revenue From 2023

$110.3M

inf %
From Previous Year
  • Revenue TTM $131.7M
  • Operating Margin TTM -40.3%
  • Gross profit TTM $0
  • Return on assets TTM -6.7%
  • Return on equity TTM -12.6%
  • Profit Margin -38.4%
  • Book Value Per Share 9.32%
  • Market capitalisation $3.05B
  • Revenue for 2021 $0
  • Revenue for 2022 $0
  • Revenue for 2023 $110.3M
  • EPS this year (TTM) $-1.03
... ...

Similar Stocks to Arcellx, Inc. - ACLX

🛑 Alert: These ten stocks could have higher potential than $ACLX 🛑

Before you buy ACLX you’ll want to see this list of ten stocks that have huge potential. Want to see if ACLX made the cut? Enter your email below

...

ACLX Frequently asked questions

The highest forecasted price for ACLX is $85.00 from cory kasimov at Evercore ISI.

The lowest forecasted price for ACLX is $70.00 from daina graybosch from Leerink Partners

The ACLX analyst ratings consensus are 10 buy ratings, 0 hold ratings, and 0 sell ratings.